Thu, Jan 29, 2015, 8:20 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • xwavve xwavve Dec 26, 2012 6:42 PM Flag

    Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

    1300 patient cabo trial -- scheduled for completion this month for primary end-point, according to ClinTrials.

    Top-line data should be forthcoming in the next few months. These type of data may result in a much broader label than people expect, and accelerate compendium listing/off-label use.

    Look for a European partner announcement in Q.1...

    Look for compendium listing beyond MTC in late Q.1-2..

    Much off-label use on the way.....

    Hmmmmm. This would seem like big news in Q.1 - - 1300 Patient Trial

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
EXEL
1.97-0.07(-3.43%)Jan 29 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.